Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00571428 · ClinicalTrials.gov registry record · Phase 4
Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD
A Phase 4 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
NCT00571428 is a Phase 4 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 33 participants.
The verdict
NCT00571428, a Phase 4 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of arformoterol tartrate inhalation solution 30μg/4mL QD (two 15μg/2mL dosed in combination) over a 24-hour period compared to arformoterol tartrate inhalation solution 15μg/2 mL BID in subjects with COPD.
Interventions
- DRUG Placebo
- DRUG Arformoterol Tartrate Inhalation Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00571428
The ClinicalTrials.gov registry entry for NCT00571428 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00571428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00571428 about?
NCT00571428 is a clinical study titled "Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD". To evaluate the efficacy and safety of arformoterol tartrate inhalation solution 30μg/4mL QD (two 15μg/2mL dosed in combination) over a 24-hour period compared to arformoterol tartrate inhalation solution 15μg/2 mL BID in subjects with COPD.
What is the current status of trial NCT00571428?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2007-11. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00571428?
The interventions under investigation include: Placebo (DRUG), Arformoterol Tartrate Inhalation Solution (DRUG).
Who is sponsoring clinical trial NCT00571428?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.